Chemistry:Povorcitinib

From HandWiki

Povorcitinib is an investigational new drug that is being evaluated for the treatment of the skin conditions hidradenitis suppurativa[1][2] and chronic prurigo.[3][4] It is a JAK1 inhibitor.[5]

References

  1. ↑ "Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies". The British Journal of Dermatology 186 (5): 803–813. May 2022. doi:10.1111/bjd.20969. PMID 34978076. 
  2. ↑ "Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study". Journal of the American Academy of Dermatology 90 (3): 521–529. March 2024. doi:10.1016/j.jaad.2023.10.034. PMID 37871805. 
  3. ↑ "Povorcitinib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800052386. 
  4. ↑ "Chronic Prurigo". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology 22 (6): 813–823. June 2024. doi:10.1111/ddg.15317. PMID 38722190. 
  5. ↑ "Prurigo nodularis: new insights into pathogenesis and novel therapeutics". The British Journal of Dermatology 190 (6): 798–810. May 2024. doi:10.1093/bjd/ljae052. PMID 38345154. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Povorcitinib&oldid=4028842"